

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hangzhou Diagens Biotechnology Co., Ltd.

杭州德適生物科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2526)

POLL RESULTS OF THE 2025 ANNUAL GENERAL MEETING HELD ON JUNE 26, 2026

According to the notice (the “**Notice**”) and the circular (the “**Circular**”) dated June 4, 2026 of the 2025 annual general meeting (the “**AGM**”) of Hangzhou Diagens Biotechnology Co., Ltd. (the “**Company**”), the AGM of the Company was held on Friday, June 26, 2026 at 2:00 p.m. by way of a hybrid meeting at Conference Room 1, 9th Floor, Building A, No. 609, Hongfeng Road, Linping District, Hangzhou, Zhejiang, PRC, with online access through an online platform at http://meetings.computershare.com/Diagens_AGM2025.

Unless otherwise defined, capitalized terms in this announcement shall have the same meanings as those defined in the Circular.

POLL RESULTS OF THE AGM

The Directors, namely Dr. Song Ning, Mr. Weng Chih-Hsin (alias Robin Weng), Dr. Xu Chen, Dr. Wu Lingqian, Mr. Yang Zehao, Mr. Cha Yang (alias Stanley Cha), Ms. Zhang Jing and Mr. Wang Kaifeng, attended the AGM in person or by electronics means.

The AGM was held in accordance with the requirements of the PRC Company Law and the Articles of Association.

The poll results in respect of all the resolutions proposed at the AGM (the “**Proposed Resolutions**”) are set out as follows:

Ordinary Resolutions		Number of Votes (%)		
		For	Against	Abstain
1.	To consider and adopt the 2025 Annual Report.	77,976,786 100.000000%	0 0.000000%	0 0.000000%
2.	To consider and approve the 2025 Profit Distribution Plan.	77,976,786 100.000000%	0 0.000000%	0 0.000000%
3.	To consider and approve the 2025 Annual Financial Report.	77,976,786 100.000000%	0 0.000000%	0 0.000000%
4.	To consider and approve the 2026 Financial Budget Report.	77,976,786 100.000000%	0 0.000000%	0 0.000000%
5.	To consider and approve the re-appointment of Ernst & Young to be the auditor of the Company for the year 2026 and authorize the Board to determine its remuneration.	77,976,786 100.000000%	0 0.000000%	0 0.000000%
Special Resolutions		Number of Votes (%)		
		For	Against	Abstain
6.	To consider and approve the grant of general mandate to the Board to issue new Shares and/or sell or transfer treasury shares not exceeding 20% of the total number of Shares in issue (excluding treasury shares), with the details of the general mandate as set out in the Circular.	77,971,836 99.993652%	4,950 0.006348%	0 0.000000%
7.	To consider and approve the grant of general mandate to the Board to repurchase H Shares not exceeding 10% of the total number of H Shares in issue (excluding treasury shares), with the details of the general mandate as set out in the Circular.	77,976,786 100.000000%	0 0.000000%	0 0.000000%
8.	To consider and approve the amendments to the Articles of Association.	77,976,786 100.000000%	0 0.000000%	0 0.000000%
Ordinary Resolutions		Number of Votes (%)		
		For	Against	Abstain
9.	To consider and approve the 2026 remuneration package of Directors.	77,976,786 100.000000%	0 0.000000%	0 0.000000%
10.	To consider and approve the confirmation of the independent Directors of the Company.	77,976,786 100.000000%	0 0.000000%	0 0.000000%

Notes:

- (1) The number of votes and the approximate percentage of total votes as stated above are based on the total number of issued Shares held by the Shareholders who attended and voted at the AGM in person or by electronic means, by authorized representative or by proxy.
- (2) For the full text of the Proposed Resolutions, please refer to the Notice as contained in the Circular.

As more than half of the votes were cast in favour of the Proposed Resolutions numbered 1 to 5 and numbered 9 to 10, all of them were duly passed as ordinary resolutions of the Company.

As more than two-thirds of the votes were cast in favour of the Proposed Resolutions numbered 6 to 8, all of them were duly passed as special resolutions of the Company.

The Company's H share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the AGM for the purpose of vote-taking.

As at the date of the AGM, the total number of issued Shares was 88,879,200 Shares, and there were no treasury shares. The total number of Shares entitling the Shareholders to attend and vote for or against the Proposed Resolutions was 88,879,200 Shares.

As at the date of the AGM, the total number of Shares held by the Shareholders or their proxies who have attended the AGM and were entitled to vote was 77,976,786 Shares, representing approximately 87.73% of the total number of issued Shares.

No Shareholders were required under the Listing Rules to abstain from voting on the Proposed Resolutions at the AGM. There was no restriction on any Shareholder to cast votes on any of the Proposed Resolutions at the AGM. There were no Shares entitling the Shareholders to attend and abstain from voting in favour of the Proposed Resolutions at the AGM pursuant to Rule 13.40 of the Listing Rules. No Shareholders has stated his/her/its intention in the Circular that he/she/it would vote against or abstain from voting on any of the Proposed Resolutions at the AGM.

By order of the Board
Hangzhou Diagens Biotechnology Co., Ltd.
Song Ning
*Chairman of the Board, Executive Director and
General Manager*

Hangzhou, PRC, June 26, 2026

As of the date of this announcement, the Board comprises: (i) Dr. Song Ning and Mr. Weng Chih-Hsin (alias Robin Weng) as executive Directors; (ii) Dr. Xu Chen, Dr. Wu Lingqian and Mr. Yang Zehao as non-executive Directors; and (iii) Mr. Cha Yang (alias Stanley Cha), Ms. Zhang Jing and Mr. Wang Kaifeng as independent non-executive Directors.